Study Type
Interventional - Drug
completed
In patients receiving a factor Xa inhibitor who are experiencing an acute major bleed, the objectives of the ANNEXa-4 study are to:
- Demonstrate the decrease in anti-fXa activity and;
- Evaluate hemostatic efficacy following andexanet treatment.
Study Design
Prospective open-label
NO. of Countries
9
NO. of Sites
81
NO. of Participants
466
Study Period
2015 - 2020
Sponsor
Portola Pharmaceuticals
Stuart Connolly
Stuart Connolly
Stuart Connolly is a Professor of Medicine at McMaster University and a cardiac electrophysiologist at Hamilton Health Sciences. He became a faculty member at McMaster University in 1983 and was awarded a full professorship in 1994. He was also appointed as the inaugural holder of the Salim Yusuf Chair in Cardiology at McMaster University.
He has published more than 270 scientific articles in the field, and is currently a member of the editorial boards for a number of prominent cardiology journals, including Heart, the American Heart Journal and the Journal of Pacing and Electrophysiology. His main research interests are focused on the evaluation of treatments for heart rhythm disorders. His academic career has been largely devoted to the design and execution of controlled clinical trials in this area.
He holds a Masters degree from Fordham University, New York, and an MD from McGill University in Montreal. He received his specialist training in cardiology at the University of Toronto and at Stanford University.
Amanda Taylor
Associate Program Manager
Amanda Taylor
Associate Program Manager
Amanda Taylor is an Associate Program Manager who currently coordinates trials in stroke, and has experience conducting trials in acute coronary syndrome and arrhythmia. Amanda joined PHRI in 2007. She holds a Bachelor of Science Degree (Honours) in Neurobiology from Brock University.
ongoing
ANNEXa-I
Thrombosis
ANNEXa-I is a randomized, multicenter, Phase 4 clinical trial of 440 patients designed to determine...
